Insulet (PODD) Revenue (2010 - 2026)

Insulet (PODD) has reported Revenue for 17 consecutive years, with $801.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Revenue rose 23.51% year-over-year to $801.7 million; the trailing twelve-month figure through Jun 2026 stood at $3.1 billion (up 29.41% YoY), and the FY2025 full-year result was $2.7 billion, up 30.73% from the prior year.
• Revenue grew to $801.7 million in Q2 2026 per PODD's latest filing, from $761.7 million in the prior quarter.
• Across five years, Revenue topped out at $801.7 million in Q2 2026 and bottomed at $295.4 million in Q1 2022.
• Historically, Revenue has averaged $519.2 million across 5 years, with a median of $499.2 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Revenue gained 13.75% in 2022, then surged 37.9% in 2023.
• Over 5 years, Revenue stood at $369.7 million in 2022, then soared by 37.9% to $509.8 million in 2023, then grew by 17.2% to $597.5 million in 2024, then soared by 31.18% to $783.8 million in 2025, then climbed by 2.28% to $801.7 million in 2026.
• According to Business Quant data, Revenue over the past three periods registered $801.7 million, $761.7 million, and $783.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.